Limited Evidence for Anticoagulation Despite High VTE Risk in Sickle Cell Disease – RPTH
RPTH Journal shared on LinkedIn about a recent article by Mosaad Almegren et al, adding:
”What’s the best anticoagulant for venous thrombosis in sickle cell disease?
Patients with sickle cell disease (SCD) face a high risk of venous thromboembolism, yet evidence guiding anticoagulation choice remains limited.
A new RPTH study compared direct oral anticoagulants (DOACs) vs warfarin in adults with SCD experiencing their first VTE.
Here’s the key signal:
- Similar rates of recurrent thrombosis and major bleeding between DOACs and warfarin.
- Clinically relevant non-major bleeding was significantly lower with DOACs.
Some context from the cohort:
- 99 patients with SCD and VTE
- Pulmonary embolism was the most common event (~65%)
- Median follow-up ~44 months
- Most DOAC use involved rivaroxaban or apixaban
Translation:
For patients with SCD and thrombosis, DOACs may offer comparable protection with less bleeding burden.
Big questions for the field:
- Should DOACs become first-line therapy for VTE in SCD?
- How long should anticoagulation continue in this high-recurrence population?
- Do SCD-specific thrombosis mechanisms require tailored anticoagulation strategies?”
Title: Management of venous thrombosis in sickle cell disease: a comparative study on the use of direct oral anticoagulants and warfarin
Authors: Mosaad Almegren, Eysa N. AlSolamy, Rayan A. Qutob, Mohammed M. Alasmari, Ali Aljeraiwi, Noura Aljuwaisri, Turki Abdulaziz Alshuaibi, Faisal Bahammam, Bader Al Rawahi, Hoor Hamed Al Farsi
Read the Full Article on RPTH
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 24, 2026, 03:36Ana Pedrero Gil: A New Approach to Post-Tonsillectomy Hemorrhage
-
Jun 24, 2026, 02:59Melissa Hollo: Making Early Anemia Detection the Standard of Care
-
Jun 24, 2026, 02:51Bruno Pougault: The Thin Line Between Bleeding and Clotting
-
Jun 23, 2026, 23:30Shunsuke Iwano: PMDA Introduces Greater Flexibility for Pediatric Factor VIII and IX Development in Japan
-
Jun 23, 2026, 23:05Rounak Dubey: ISBT Academy Session on Agentic AI
-
Jun 23, 2026, 22:59Mohammed Maher Babiker: When ‘Low Platelets’ aren’t Really Low
-
Jun 23, 2026, 22:49Giovanni Merlino: Why Does Stress Hyperglycemia Worsen Stroke Outcomes?
-
Jun 23, 2026, 22:41Tareq Abadl: Coombs Test – The Key to Detecting Immune-Mediated Hemolysis
-
Jun 23, 2026, 22:32How WFH Impacted the Bleeding Disorders Community in 2025